{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:23:18Z","timestamp":1787289798511,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Reliable and accessible tools for estimating axillary pathologic complete response (ax-pCR) after neoadjuvant therapy (NAT) remain limited. This study evaluated whether routinely available biomarkers measured before and after NAT provide complementary information for ax-pCR prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of patients with clinically node-positive, non-metastatic breast cancer who underwent NAT followed by surgery. Clinicopathological characteristics, treatment information, serum albumin, and inflammatory indices measured before and after NAT were evaluated. Biomarker cutoffs were selected using the maximum Youden index. Variables with P&amp;lt;0.05 in univariable analyses were entered into multivariable logistic regression. A nomogram was constructed from variables that remained significant in the initial multivariable model. Discrimination, calibration, clinical net benefit and optimism-corrected performance were assessed using bootstrap resampling and decision-curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 158 patients, ax-pCR occurred in 74 (46.8%). In the initial multivariable model, HER2 positivity and pre-NAT albumin \u226543.95 g\/L were associated with higher odds of ax-pCR, whereas clinical stage III and post-NAT NLR \u22654.58 were associated with lower odds. The four-variable nomogram achieved an apparent AUC of 0.782 (95% CI, 0.708\u20130.851). At the maximum-Youden-index threshold, sensitivity was 74.3% (95% CI, 63.3%\u201382.9%) and specificity was 73.8% (95% CI, 63.5%\u201382.0%). After bootstrap correction, the AUC was 0.766, the calibration slope was 0.908 and the Brier score was 0.200. Decision-curve analysis suggested potential net benefit across a range of threshold probabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical characteristics and blood-based biomarkers measured before and after NAT provided complementary information for ax-pCR estimation. The nomogram showed moderate discrimination and reasonable internal calibration. External validation is required before clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1937807","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:01Z","timestamp":1787286181000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a nomogram for predicting axillary pathologic complete response after neoadjuvant therapy in clinically node-positive breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Bin","family":"Li","sequence":"first","affiliation":[{"name":"Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Radiation Oncology Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College;","place":["Nanchang, China"]},{"name":"Yichun Vocational Technical College of Medicine, The Affiliated Hospital of Yichun Vocational Technical College","place":["Yichun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Yi","sequence":"additional","affiliation":[{"name":"Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Radiation Oncology Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College;","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenghua","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology (2024SSY06041), Jiangxi Clinical Research Center for Cancer, Jiangxi Health Commission (JXHC) Key Laboratory of Tumor Microenvironment and Immunoregulation, Jiangxi Key Laboratory of Tumor Metastasis of Jiangxi Health Commission","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Bao","sequence":"additional","affiliation":[{"name":"Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Radiation Oncology Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College;","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"He","sequence":"additional","affiliation":[{"name":"Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Radiation Oncology Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College;","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyu","family":"He","sequence":"additional","affiliation":[{"name":"Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Radiation Oncology Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College;","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[{"name":"Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Radiation Oncology Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College;","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17297-7","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in ER+\/HER2- locally advanced breast cancer","volume":"32","author":"Wang","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24874","article-title":"Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel","volume":"116","author":"Kaufmann","year":"2010","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70076-7","article-title":"Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis","volume":"14","author":"DiSipio","year":"2013","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial","volume":"98","author":"Mansel","year":"2006","journal-title":"J Natl Cancer Institute"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"Jama"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5958-4","article-title":"Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of American Society of Breast Surgeons members","volume":"24","author":"Caudle","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02021-z","article-title":"PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer","volume":"128","author":"Shi","year":"2023","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13058-017-0846-1","article-title":"Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI","volume":"19","author":"Braman","year":"2017","journal-title":"Breast Cancer Research: BCR"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.70100","article-title":"Endocrine resistance score based on three key genes predicts prognosis and reveals potential therapeutic targets for ER+HER2- breast cancer","volume":"59","author":"Ping","year":"2026","journal-title":"Cell Proliferation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis","volume":"19","author":"Ethier","year":"2017","journal-title":"Breast Cancer Research: BCR"},{"key":"B19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41523-025-00862-4","article-title":"Nomogram for predicting axillary pathologic complete response in cN2\u20133 breast cancer after neoadjuvant chemotherapy","volume":"11","author":"Oh","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6345-5","article-title":"A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer","volume":"25","author":"Kantor","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5277-1","article-title":"Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer","volume":"23","author":"Vila","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1042394","article-title":"A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer","volume":"13","author":"Shi","year":"2022","journal-title":"Front Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7150\/jca.62830","article-title":"Discrepancy of breast and axillary pathologic complete response and outcomes in different subtypes of node-positive breast cancer after neoadjuvant chemotherapy","volume":"12","author":"Chen","year":"2021","journal-title":"J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32830","article-title":"A nomogram for predicting axillary pathologic complete response in hormone receptor-positive breast cancer with cytologically proven axillary lymph node metastases","volume":"126","author":"Guo","year":"2020","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05214-y","article-title":"Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy","volume":"176","author":"Choi","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-022-06726-7","article-title":"Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer","volume":"307","author":"von Au","year":"2023","journal-title":"Arch Gynecology Obstetrics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1186\/s12885-021-08458-4","article-title":"Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy","volume":"21","author":"Dong","year":"2021","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040958","article-title":"Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review","volume":"12","author":"Corbeau","year":"2020","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188762","article-title":"Tumor-associated neutrophils and neutrophil-targeted cancer therapies","volume":"1877","author":"Que","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3616","article-title":"Neutrophils in cancer development and progression: roles, mechanisms, and implications (Review)","volume":"49","author":"Zhang","year":"2016","journal-title":"Int J Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000036315","article-title":"Peripheral blood inflammatory indexes in breast cancer: a review","volume":"102","author":"Xie","year":"2023","journal-title":"Medicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1937807\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:02Z","timestamp":1787286182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1937807\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1937807"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1937807","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1937807"}}